Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled syringe or Auto-Injector in Patients with Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate. [Farmakokinetické hodnocení tabalumabu po podkožním podání pomocí předplněné injekční stříkačky nebo autoinjektoru u pacientů s revmatoidní artritidou, kteří měli nedostačující odezvu na metotrexát].
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Tabalumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics; Registrational
- Sponsors Eli Lilly and Company
- 07 Feb 2013 Status changed from suspended to discontinued, as reported in an Eli Lilly media release.
- 13 Dec 2012 Status changed from recruiting to suspended, as reported in an Eli Lilly media release.
- 12 Dec 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2012-001618-40)